NEW
YORK, June 27, 2024 /PRNewswire/ -- The global
binge-eating disorder treatment market size is estimated to grow by
USD 568.7 million from 2024-2028,
according to Technavio. The market is estimated to grow at a
CAGR of 6.78% during the forecast period. Increasing
prevalence of binge-eating disorder is driving market growth, with
a trend towards development and approval of new drugs. However,
side effects of binge-eating disorder drugs poses a challenge. Key
market players include Alvogen Iceland ehf, Bausch Health Companies
Inc., Chronos Therapeutics Ltd., Currax Pharmaceuticals LLC, Eli
Lilly and Co., Johnson and Johnson Services Inc., Lupin Ltd.,
Omeros Corp., Pyramid Healthcare Inc., Rosewood Centers for Eating
disorders, Sumitomo Pharma Co. Ltd., Takeda Pharmaceutical Co.
Ltd., Timberline Knolls Residential Treatment Center, Tonix
Pharmaceuticals Holding Corp., Tryp Therapeutics Inc., Viatris
Inc., VIVUS LLC, and Walden Behavioral Care.
Get a detailed analysis on regions, market
segments, customer landscape, and companies- View the
snapshot of this report
Binge-Eating
Disorder Treatment Market Scope
|
Report
Coverage
|
Details
|
Base year
|
2023
|
Historic
period
|
2018 - 2022
|
Forecast
period
|
2024-2028
|
Growth momentum &
CAGR
|
Accelerate at a CAGR of
6.78%
|
Market growth
2024-2028
|
USD 568.7
million
|
Market
structure
|
Concentrated
|
YoY growth 2022-2023
(%)
|
6.24
|
Regional
analysis
|
North America, Europe,
Asia, and Rest of World (ROW)
|
Performing market
contribution
|
North America at
35%
|
Key
countries
|
US, UK, Germany, China,
and India
|
Key companies
profiled
|
Alvogen Iceland ehf,
Bausch Health Companies Inc., Chronos Therapeutics Ltd., Currax
Pharmaceuticals LLC, Eli Lilly and Co., Johnson and Johnson
Services Inc., Lupin Ltd., Omeros Corp., Pyramid Healthcare Inc.,
Rosewood Centers for Eating disorders, Sumitomo Pharma Co. Ltd.,
Takeda Pharmaceutical Co. Ltd., Timberline Knolls Residential
Treatment Center, Tonix Pharmaceuticals Holding Corp., Tryp
Therapeutics Inc., Viatris Inc., VIVUS LLC, and Walden Behavioral
Care
|
Market Driver
The binge-eating disorder treatment market is experiencing
significant growth due to the increasing prevalence of this
condition. Pharmaceutical companies are actively developing new
treatments for binge-eating disorders, with several initiatives
underway. For instance, Tonix Pharmaceuticals Holding Corp. And
Massachusetts General Hospital announced a collaboration in 2022 to
assess TNX-1900 as a potential treatment for patients diagnosed
with both binge-eating disorder and obesity. The planned phase 2
clinical trial, which was set to launch in the second half of 2022,
is a randomized, double-blind, placebo-controlled study involving
60 patients. Additionally, Tryp Therapeutics reported interim
results from its Phase II trial with psilocybin (TRP-8803) for
binge-eating disorder treatment, showing an average reduction of
80% in daily binge-eating episodes. These developments indicate a
positive impact on the global binge-eating disorder treatment
market during the forecast period.
The Binge Eating Disorder (BED) treatment market is experiencing
significant growth due to the rising prevalence of BED, Bulimia,
and other eating disorders. This market caters to patients
diagnosed with psychological and non-psychological problems,
including comorbidities like general medical illnesses, obesity,
diabetes, hypertension, chronic pain, anxiety disorders, mood
disorders, impulse-control disorders, and substance use disorders.
Doctors are focusing on individualized treatment options for
patients, including psychotherapy and medications. Antidepressant
drugs, such as serotonergic antidepressants, are commonly used to
treat BED. New treatments, like Lisdexamfetamine with
Methylphenidate and Centanafadine Sustained-release Tablets, are
undergoing Phase 2 and Phase 4 clinical trials. Costly treatment
for eating disorders can be a challenge for patients. However,
healthcare services continue to offer various treatment therapies,
including medication and psychotherapy, to help manage symptoms of
excessive feeding and impairments related to overweight or normal
weight profiles. Other medical disorders, such as gastrointestinal
problems, headaches, and sleeplessness, can also be addressed
through these treatments. Anorexia and its related disorders, such
as bulimia, continue to pose a challenge in the treatment market.
The use of medications like Solriamfetol and Dasotraline is being
explored to address the complex nature of these disorders. The
overall healthcare expenditures for treating eating disorders are
expected to increase as more effective and accessible treatment
options become available.
Research report provides comprehensive data on
impact of trend. For more details- Download a Sample
Report
Market Challenges
- Binge-eating disorder (BED) is a serious mental health
condition characterized by recurrent episodes of eating large
quantities of food in a short period, often accompanied by feelings
of shame or guilt. While binge-eating disorder drugs offer
potential treatment options, their use comes with significant
risks, particularly during pregnancy. These drugs have been linked
to congenital abnormalities, stillbirths, spontaneous abortion, low
birth weight, gestational hypertension, prematurity, postpartum
hemorrhage, and delayed motor development in newborns. Furthermore,
binge-eating disorder drugs can cause physical side effects such as
headaches, insomnia/hypersomnia, and gastric distress, as well as
emotional side effects like hyperactivity, hostility, emotional
lability, irritability, and self-harm. These side effects may
hinder the growth of the global binge-eating disorder treatment
market, as they impede patient compliance and contribute to
treatment resistance in up to 30% of cases. Therefore, the
uncertainty surrounding the safety and efficacy of binge-eating
disorder drugs, particularly for pregnant women, presents a
significant challenge for the market's growth during the forecast
period.
- The Binge-Eating Disorder (BED) treatment market faces several
challenges in addressing this medical disorder characterized by
excessive feeding, often leading to overweight or normal weight
profiles. Patients with BED often suffer from comorbid
mood disorders, impulse-control disorders, and substance use
disorders. Treatment options include psychotherapy, antidepressant
drugs, and medication from the Pharmaceuticals category, such
as Lisdexamfetamine with Methylphenidate,
Centanafadine Sustained-Release Tablets, and
Serotonergic antidepressants like Solriamfetol
and Dasotraline. However, costly treatment and
potential medical complications, including cardiac diseases,
insomnia, gastroesophageal reflux disease, headaches,
and sleeplessness, pose significant challenges. Doctors play a
crucial role in diagnosing and treating BED, but healthcare
expenditures continue to rise due to the high demand for healthcare
services. The Phase 2 and 4 clinical trials of these treatments
demonstrate promising results, but more research is needed to
individualize treatment and improve patient outcomes. (Biological
Psychiatry, Psychiatry Research)
For more insights on driver and
challenges - Request a sample report!
Segment Overview
This binge-eating disorder treatment market report extensively
covers market segmentation by
- Distribution Channel
- Type
- 2.1 Antidepressants
- 2.2 Anticonvulsants
- 2.3 Stimulants and others
- Geography
- 3.1 North America
- 3.2 Europe
- 3.3 Asia
- 3.4 Rest of World (ROW)
1.1 Offline- In 2023, the offline sector held the
largest share of the global binge-eating disorder treatment market.
This segment's dominance can be attributed to several factors.
Offline retailers offer product assurance, authenticity, and
verification, making them a preferred choice for customers.
Additionally, offline stores provide convenience, personalization,
and personal support, which fuels their expansion during the
forecast period. The advantages of offline stores include a wide
geographical presence, ease of production and inventory management,
and efficient goods transportation. Market players invest in
brick-and-mortar stores to increase their regional and global
shares. The growth of the retail sector, which improves access to
binge-eating disorder treatment drugs, is expected to accelerate
offline segment growth, thereby boosting the overall market
expansion.
For more information on market segmentation with geographical
analysis including forecast (2024-2028) and historic data
(2017-2021) - Download a Sample Report
Learn and explore more about Technavio's in-depth research
reports
The Paracetamol market is experiencing robust growth due to its
widespread use as an analgesic and antipyretic. With increasing
prevalence of chronic diseases and rising consumer awareness, the
demand for paracetamol is on the rise globally. Meanwhile, the
Antibiotics market continues to expand, driven by the persistent
need to combat bacterial infections. However, the market faces
challenges such as antibiotic resistance and stringent regulations.
Innovations in antibiotic development and strategic collaborations
are pivotal in addressing these issues, ensuring sustained market
growth and effective healthcare solutions.
Research Analysis
Binge eating disorder (BED) is a serious mental health condition
characterized by recurrent episodes of excessive food consumption,
often accompanied by feelings of guilt or shame. This eating
disorder differs from bulimia in that there's no purging or
compensatory behaviors. BED affects individuals of all weight
profiles, including those who are overweight, obese, or normal
weight. Comorbid psychological problems, such as depression and
anxiety, are common in individuals with BED. Additionally,
individuals with BED may experience various non-psychological
problems, including medical disorders like obesity, diabetes,
hypertension, chronic pain, and other comorbid disorders. While
there are no specific medications approved solely for BED, some
medications, such as antidepressants and anti-obesity drugs, may be
used to manage symptoms and underlying conditions. Treatment for
BED typically involves a combination of psychological
interventions, such as cognitive-behavioral therapy and
psychotherapy, to help individuals understand and change their
eating patterns and address any underlying emotional or
psychological issues.
Market Research Overview
Binge eating disorder (BED) is a type of eating disorder
characterized by recurrent episodes of excessive food consumption,
often accompanied by feelings of guilt, depression, or anxiety. BED
can affect individuals of all weight profiles and is often
accompanied by bulimia, anxiety disorders, mood disorders,
impulse-control disorders, and substance use disorders. Comorbid
medical problems, such as obesity, diabetes, hypertension, chronic
pain, and gastrointestinal issues, can also be present.
Psychological problems, including impairments in social and
occupational functioning, can result from BED. Treatment options
include psychotherapy, such as cognitive-behavioral therapy and
interpersonal psychotherapy, and medications, including
antidepressant drugs and lisdexamfetamine with methylphenidate. The
diagnosis of BED involves a thorough evaluation by healthcare
professionals, including doctors and mental health specialists.
Treatment therapy can be costly and may involve a combination of
medication and healthcare services. Phase 2 and 4 clinical trials
are currently underway for new treatments, such as Centanafadine
Sustained-Release Tablets, solriamfetol, and dasotraline. BED can
also lead to medical complications, including cardiac diseases,
insomnia, and gastroesophageal reflux disease. The Biological
Psychiatry and Psychiatry Research journals have published numerous
studies on the causes and treatments of BED and related eating
disorders. It is important to note that BED is a complex medical
disorder and treatment should be individualized based on the
specific needs and circumstances of each patient. Other eating
disorders, such as anorexia, can also present with similar symptoms
and should be considered in the diagnostic process.
Table of Contents:
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation
- Distribution Channel
-
- Type
-
- Antidepressants
- Anticonvulsants
- Stimulants And Others
- Geography
-
- North America
- Europe
- Asia
- Rest Of World (ROW)
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix
About Technavio
Technavio is a leading global technology research and advisory
company. Their research and analysis focuses on emerging market
trends and provides actionable insights to help businesses identify
market opportunities and develop effective strategies to optimize
their market positions.
With over 500 specialized analysts, Technavio's report library
consists of more than 17,000 reports and counting, covering 800
technologies, spanning across 50 countries. Their client base
consists of enterprises of all sizes, including more than 100
Fortune 500 companies. This growing client base relies on
Technavio's comprehensive coverage, extensive research, and
actionable market insights to identify opportunities in existing
and potential markets and assess their competitive positions within
changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
View original content to download
multimedia:https://www.prnewswire.com/news-releases/binge-eating-disorder-treatment-market-size-is-set-to-grow-by-usd-568-7-million-from-2024-2028--increasing-prevalence-of-binge-eating-disorder-boost-the-market-technavio-302184121.html
SOURCE Technavio